This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical-devices: Archive
Intuitive Surgical's Record Cash Flow Gives It an Innovation Advantage
by Harshit Gupta
ISRG's record cash flow is fueling R&D, manufacturing expansion and over 100 da Vinci 5 updates, strengthening its innovation edge.
ISRGPositive Net Change BSXNegative Net Change MDTNegative Net Change
medical medical-devices
Arcturus Therapeutics (ARCT) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
ARCTPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
ISRG vs. MDT: Which Surgical Robot Stock Is the Smarter Buy?
by Harshit Gupta
Intuitive Surgical leads surgical robotics with faster procedure growth and recurring revenue, while Medtronic offers a cheaper, diversified growth profile.
MDTNegative Net Change ISRGPositive Net Change
medical medical-devices
DVA & Humana Expand Value-Based Care for Kidney Disease Patients
by Zacks Equity Research
DaVita expands its Humana partnership to earlier-stage kidney disease, bringing value-based care to over 10,000 Medicare Advantage members.
DVAPositive Net Change WSTPositive Net Change GMEDPositive Net Change VCYTNegative Net Change
medical medical-devices
Here's Why You Should Retain IQVIA Stock in Your Portfolio Now
by Zacks Equity Research
IQV shares rise 21.7% in a month as data assets, AI-enabled technology and strong cash flow support growth despite liquidity and pricing risks.
IQVPositive Net Change GMEDPositive Net Change CRBUNegative Net Change
medical medical-devices
Do Options Traders Know Something About Stryker Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to SYK stock based on the movements in the options market lately.
SYKPositive Net Change
medical medical-devices
Strategic Education (STRA) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
STRAPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Pulmonx Corporation (LUNG) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
LUNGNo Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
MDT's Q1 Earnings on Deck: How Should You Play the Stock Now?
by Moumi Mondal
Medtronic's Q1 results may reflect strong growth across Cardiovascular, Neuroscience and Diabetes, but earnings beat signals remain mixed.
MDTNegative Net Change BSXNegative Net Change EWNegative Net Change
earnings-preview medical medical-devices
Here's Why You Should Retain McKesson Stock in Your Portfolio for Now
by Zacks Equity Research
MCK's specialty distribution, oncology and technology businesses are fueling growth, while drug-pricing pressure and policy shifts pose risks.
MCKPositive Net Change WSTPositive Net Change GMEDPositive Net Change VCYTNegative Net Change
medical medical-devices